AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...
Tallying up a wide range of investments, AstraZeneca said it is pumping $2.5 billion into Beijing. The figure includes ...
We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...
In a bold move to cement its foothold in China’s booming biopharmaceutical sector, AstraZeneca announced Friday a $2.5 billion investment in Beijing over the next five years. The pharmaceutical titan ...
Pharmaceutical Technology on MSN3d
AstraZeneca and Alteogen agree on ALT-B4 platform tech"AstraZeneca and Alteogen agree on ALT-B4 platform tech" was originally created and published by Pharmaceutical Technology, a ...
AstraZeneca (AZN) and Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform ...
Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...
AstraZeneca is working on strengthening its oncology product portfolio through label expansions of existing products and progressing oncology pipeline candidates. Oncology sales (comprising around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback